Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4245)
All Articles published online
|
Jan 14, 2010 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wolf S, Lorenz J, Mössner J, Wiedmann M. Treatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance. World J Gastroenterol 2010; 16(2): 156-166 [PMID: 20066734 DOI: 10.3748/wjg.v16.i2.156] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i2/156.htm |
| Number | Citing Articles |
| 1 |
Shanrong Shu, Xiaomao Li, Yuebo Yang, Yu Zhang, Tian Li, Changyan Liang, Jing Wan. Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. International Immunopharmacology 2011; 11(2): 244 doi: 10.1016/j.intimp.2010.11.031
|
| 2 |
Pushpendra Singh, Jimi Marin Alex, Felix Bast. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Medical Oncology 2014; 31(1) doi: 10.1007/s12032-013-0805-3
|
| 3 |
Yaman Suleiman, Amit Mahipal, David Shibata, Erin M. Siegel, Helen Jump, William J. Fulp, Gregory M. Springett, Richard Kim. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology 2015; 76(3): 481 doi: 10.1007/s00280-015-2814-8
|
| 4 |
Mirella Pastore, Giulia Lori, Alessandra Gentilini, Maria Letizia Taddei, Giovanni Di Maira, Claudia Campani, Stefania Recalcati, Pietro Invernizzi, Fabio Marra, Chiara Raggi. Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells 2020; 9(3): 596 doi: 10.3390/cells9030596
|
| 5 |
Chao-En Wu, Ming-Huang Chen, Chun-Nan Yeh. mTOR Inhibitors in Advanced Biliary Tract Cancers. International Journal of Molecular Sciences 2019; 20(3): 500 doi: 10.3390/ijms20030500
|
| 6 |
Hirokazu Ohashi, Yasushi Adachi, Hiroyuki Yamamoto, Hiroaki Taniguchi, Katsuhiko Nosho, Hiromu Suzuki, Yoshiaki Arimura, Kohzoh Imai, David P. Carbone, Yasuhisa Shinomura. Insulin‐like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers. Cancer Science 2012; 103(2): 252 doi: 10.1111/j.1349-7006.2011.02138.x
|
| 7 |
Judith Schaffrath, Hans-Joachim Schmoll, Wieland Voigt, Lutz P. Müller, Carsten Müller-Tidow, Thomas Mueller, Aamir Ahmad. Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLOS ONE 2017; 12(6): e0178930 doi: 10.1371/journal.pone.0178930
|
| 8 |
Francesca Corti, Federico Nichetti, Alessandra Raimondi, Monica Niger, Natalie Prinzi, Martina Torchio, Elena Tamborini, Federica Perrone, Giancarlo Pruneri, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treatment Reviews 2019; 72: 45 doi: 10.1016/j.ctrv.2018.11.001
|
| 9 |
Varsha P. Brahmkhatri, Chinmayi Prasanna, Hanudatta S. Atreya. Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/538019
|
| 10 |
Rosalyn D. Ferguson, Nyosha Alikhani, Archana Vijayakumar, Yvonne Fierz, Dara Cannata, Shoshana Yakar. Insulin-like Growth Factors and Cancer. 2012; : 105 doi: 10.1007/978-1-4614-0598-6_6
|
| 11 |
Carmen Avendaño, J. Carlos Menéndez. Medicinal Chemistry of Anticancer Drugs. 2023; : 493 doi: 10.1016/B978-0-12-818549-0.00018-2
|
| 12 |
Kenji Takeuchi, Fumiaki Ito. Receptor Tyrosine Kinases and Targeted Cancer Therapeutics. Biological and Pharmaceutical Bulletin 2011; 34(12): 1774 doi: 10.1248/bpb.34.1774
|
| 13 |
Shanrong Shu, Yuebo Yang, Xiaomao Li, Tian Li, Yu Zhang, Chengfang Xu, Changyan Liang, Xiaoyun Wang. Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro. Molecular and Cellular Biochemistry 2011; 353(1-2): 225 doi: 10.1007/s11010-011-0790-9
|
| 14 |
Carmen Avendaño, J. Carlos Menéndez. Medicinal Chemistry of Anticancer Drugs. 2015; : 391 doi: 10.1016/B978-0-444-62649-3.00010-7
|
| 15 |
María Sol Brassesco, Julia Alejandra Pezuk, Andressa Gois Morales, Jaqueline Carvalho de Oliveira, Gabriela Molinari Roberto, Glenda Nicioli da Silva, Harley Francisco de Oliveira, Carlos Alberto Scrideli, Luiz Gonzaga Tone. In vitro targeting of Polo-like kinase 1 in bladder carcinoma. Cancer Biology & Therapy 2013; 14(7): 648 doi: 10.4161/cbt.25087
|
| 16 |
Wen-Ming Cong, You-Wen Qian. Surgical Pathology of Hepatobiliary Tumors. 2017; : 307 doi: 10.1007/978-981-10-3536-4_9
|
| 17 |
Ping Zhou, Sarah C. Baumgarten, Yanguang Wu, Jill Bennett, Nicola Winston, Jennifer Hirshfeld-Cytron, Carlos Stocco. IGF-I Signaling Is Essential for FSH Stimulation of AKT and Steroidogenic Genes in Granulosa Cells. Molecular Endocrinology 2013; 27(3): 511 doi: 10.1210/me.2012-1307
|
| 18 |
Philippe Icard, Mauro Loi, Zherui Wu, Antonin Ginguay, Hubert Lincet, Edouard Robin, Antoine Coquerel, Diana Berzan, Ludovic Fournel, Marco Alifano. Metabolic Strategies for Inhibiting Cancer Development. Advances in Nutrition 2021; 12(4): 1461 doi: 10.1093/advances/nmaa174
|
| 19 |
Aram F. Hezel, Vikram Deshpande, Andrew X. Zhu. Genetics of Biliary Tract Cancers and Emerging Targeted Therapies. Journal of Clinical Oncology 2010; 28(21): 3531 doi: 10.1200/JCO.2009.27.4787
|
| 20 |
J A Pezuk, M S Brassesco, A G Morales, J C de Oliveira, R G de Paula Queiroz, H R Machado, C G Carlotti, L Neder, C A Scrideli, L G Tone. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Therapy 2013; 20(9): 499 doi: 10.1038/cgt.2013.46
|
| 21 |
Andrew X. Zhu, Aram F. Hezel. Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities. Hepatology 2011; 53(2): 695 doi: 10.1002/hep.24145
|
| 22 |
Rujiao Liu, Wenbo Tang, Xiaotian Han, Ruixuan Geng, Chenchen Wang, Zhe Zhang. Hepatocyte growth factor‑induced mesenchymal‑epithelial transition factor activation leads to insulin‑like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells. Oncology Letters 2018; doi: 10.3892/ol.2018.9414
|
| 23 |
Amy L. Myers, Lin Lin, Derek J. Nancarrow, Zhuwen Wang, Daysha Ferrer-Torres, Dafydd G. Thomas, Mark B. Orringer, Jules Lin, Rishindra M. Reddy, David G. Beer, Andrew C. Chang. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma. Oncotarget 2015; 6(28): 25897 doi: 10.18632/oncotarget.4532
|